← Back to Search

Unknown

Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

Phase 1
Waitlist Available
Research Sponsored by CSL Behring
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new medicine called CSL889 to see if it is safe for people with sickle cell disease. The study will also look at how the medicine moves through and affects their bodies. Researchers will start with small amounts and increase them over time to find the best amount.

Eligible Conditions
  • Sickle Cell Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

8Treatment groups
Experimental Treatment
Group I: CSL889 Cohort B2 (high dose)Experimental Treatment1 Intervention
CSL889 administered as a single IV infusion
Group II: CSL889 Cohort B1 (low dose)Experimental Treatment1 Intervention
CSL889 administered as a single IV infusion
Group III: CSL889 Cohort A6 (Dose 6)Experimental Treatment1 Intervention
CSL889 administered as a single IV infusion
Group IV: CSL889 Cohort A5 (Dose 5)Experimental Treatment1 Intervention
CSL889 administered as a single IV infusion
Group V: CSL889 Cohort A4 (Dose 4)Experimental Treatment1 Intervention
CSL889 administered as a single IV infusion
Group VI: CSL889 Cohort A3 (Dose 3)Experimental Treatment1 Intervention
CSL889 administered as a single IV infusion
Group VII: CSL889 Cohort A2 (Dose 2)Experimental Treatment1 Intervention
CSL889 administered as a single IV infusion
Group VIII: CSL889 Cohort A1 (Dose 1)Experimental Treatment1 Intervention
CSL889 administered as a single IV infusion
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CSL889
2021
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

CSL BehringLead Sponsor
199 Previous Clinical Trials
1,205,053 Total Patients Enrolled
Study DirectorStudy DirectorCSL Behring
1,281 Previous Clinical Trials
500,474 Total Patients Enrolled
~6 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top